Windtree Therapeutics (WINT) Competitors $0.52 -0.02 (-3.58%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$0.52 +0.00 (+0.08%) As of 08/14/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock WINT vs. CHRO, ADXN, CLRB, CYCN, SNPX, TAOX, BTAI, TLPH, KZIA, and BMRAShould you be buying Windtree Therapeutics stock or one of its competitors? The main competitors of Windtree Therapeutics include Chromocell Therapeutics (CHRO), Addex Therapeutics (ADXN), Cellectar Biosciences (CLRB), Cyclerion Therapeutics (CYCN), Synaptogenix (SNPX), Synaptogenix (TAOX), BioXcel Therapeutics (BTAI), Talphera (TLPH), Novogen (KZIA), and Biomerica (BMRA). These companies are all part of the "pharmaceutical products" industry. Windtree Therapeutics vs. Its Competitors Chromocell Therapeutics Addex Therapeutics Cellectar Biosciences Cyclerion Therapeutics Synaptogenix Synaptogenix BioXcel Therapeutics Talphera Novogen Biomerica Chromocell Therapeutics (NYSE:CHRO) and Windtree Therapeutics (NASDAQ:WINT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation. Which has stronger valuation and earnings, CHRO or WINT? Chromocell Therapeutics is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChromocell TherapeuticsN/AN/A-$7.38M-$1.24-1.08Windtree TherapeuticsN/AN/A-$1.79M-$823.470.00 Do analysts recommend CHRO or WINT? Windtree Therapeutics has a consensus target price of $350.00, suggesting a potential upside of 67,650.68%. Given Windtree Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Windtree Therapeutics is more favorable than Chromocell Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Chromocell Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Windtree Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is CHRO or WINT more profitable? Chromocell Therapeutics' return on equity of 0.00% beat Windtree Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Chromocell TherapeuticsN/A N/A -453.90% Windtree Therapeutics N/A -227.93%-56.46% Do institutionals & insiders have more ownership in CHRO or WINT? 78.0% of Chromocell Therapeutics shares are held by institutional investors. Comparatively, 29.3% of Windtree Therapeutics shares are held by institutional investors. 16.4% of Chromocell Therapeutics shares are held by insiders. Comparatively, 0.3% of Windtree Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media favor CHRO or WINT? In the previous week, Windtree Therapeutics had 5 more articles in the media than Chromocell Therapeutics. MarketBeat recorded 5 mentions for Windtree Therapeutics and 0 mentions for Chromocell Therapeutics. Windtree Therapeutics' average media sentiment score of 0.80 beat Chromocell Therapeutics' score of 0.00 indicating that Windtree Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Chromocell Therapeutics Neutral Windtree Therapeutics Positive Which has more risk and volatility, CHRO or WINT? Chromocell Therapeutics has a beta of 3.63, indicating that its stock price is 263% more volatile than the S&P 500. Comparatively, Windtree Therapeutics has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500. SummaryWindtree Therapeutics beats Chromocell Therapeutics on 7 of the 12 factors compared between the two stocks. Get Windtree Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for WINT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding WINT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart WINT vs. The Competition Export to ExcelMetricWindtree TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.96M$3.10B$5.61B$9.84BDividend YieldN/A2.23%4.61%4.07%P/E Ratio0.0020.4930.2925.74Price / SalesN/A356.37463.41115.83Price / CashN/A43.0338.2159.48Price / Book0.018.608.826.15Net Income-$1.79M-$54.65M$3.25B$265.06M7 Day Performance-5.59%5.86%3.70%2.60%1 Month Performance-37.65%8.86%5.84%2.83%1 Year Performance-99.91%13.33%29.92%25.58% Windtree Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)WINTWindtree Therapeutics2.8772 of 5 stars$0.52-3.6%$350.00+67,650.7%-99.9%$1.96MN/A0.0030Upcoming EarningsShort Interest ↓Gap DownCHROChromocell TherapeuticsN/A$1.34+6.3%N/A-83.0%$8.69MN/A-1.084Gap UpHigh Trading VolumeADXNAddex Therapeutics2.7389 of 5 stars$8.24+1.7%$30.00+264.3%+3.0%$8.58M$460K-24.2230CLRBCellectar Biosciences2.7663 of 5 stars$5.06+7.2%$375.00+7,311.1%-92.6%$8.54MN/A-0.2310News CoverageAnalyst ForecastShort Interest ↑CYCNCyclerion Therapeutics2.7174 of 5 stars$2.79+7.5%N/A-26.3%$8.33M$2M-2.4030Short Interest ↓SNPXSynaptogenixN/A$5.99-5.4%N/A+156.3%$8.33MN/A-0.594TAOXSynaptogenixN/A$6.49+8.3%N/AN/A$8.32MN/A-0.644Positive NewsGap DownBTAIBioXcel Therapeutics4.4611 of 5 stars$2.54+85.4%$42.60+1,577.2%-56.3%$8.30M$2.27M-0.1990Earnings ReportShort Interest ↓Gap DownHigh Trading VolumeTLPHTalphera3.3844 of 5 stars$0.40+0.1%$5.00+1,140.7%-50.0%$8.25M$650K-0.9019News CoverageNegative NewsEarnings ReportShort Interest ↓Gap UpKZIANovogen3.9843 of 5 stars$8.34+2.0%$14.00+67.9%-53.7%$8.24M$1.51M0.0012Short Interest ↓Gap DownBMRABiomerica1.1633 of 5 stars$3.15-2.5%N/A+43.9%$8.23M$5.41M-1.3660News CoverageShort Interest ↓ Related Companies and Tools Related Companies CHRO Competitors ADXN Competitors CLRB Competitors CYCN Competitors SNPX Competitors TAOX Competitors BTAI Competitors TLPH Competitors KZIA Competitors BMRA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:WINT) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Windtree Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Windtree Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.